Document is current
Any future updates will be listed below
-
Authors
Tian, Yanhua
Xu, Jiachen
Chu, Qian
Duan, Jianchun
Zhang, Jianjun
Bai, Hua
Yang, Zhenlin
Fang, Wenfeng
Cai, Liangliang
Wan, Rui
Fei, Kailun
He, Jie
Gao, Shugeng
Zhang, Li
Wang, Zhijie
Wang, Jie
-
Funding
Funding for this research was provided by:
National Natural Sciences Foundation Key Program (81630071)
CAMS Innovation Fund for Medical Sciences (2016-I2M-3-008)
Aiyou Foundation (KY201701)
Ministry of Education Innovation Team development project (IRT-17R10)
CAMS Key lab of translational research on lung cancer (2018PT31035)
China National Natural Sciences Foundation (81871889)
National Key R&D Program of China (2019YFC1315700)
- License Information
-
More Information
Article History
Received: 22 February 2020
Accepted: 2 July 2020
First Online: 26 August 2020
Ethics approval and consent to participate
: Samples for the 89 early-stage NSCLC patients and 73 advanced NSCLC patients from ZS immunotherapy cohort were procured under the protocol by the ethics committees of the National Cancer Center and the ethical review board of Sun Yat-sen University Cancer Center. The ethics approval number for this study is: NCC2018-092.
: No potential conflicts of interest were disclosed by the authors.
